4.6 Article

Peroxisome proliferator-activated receptor gamma is required for regulatory CD4(+) T cell-mediated protection against colitis

期刊

JOURNAL OF IMMUNOLOGY
卷 178, 期 5, 页码 2940-2949

出版社

AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.178.5.2940

关键词

-

向作者/读者索取更多资源

Peroxisome proliferator-activated receptor (PPAR) gamma activation has been implicated in the prevention of immunoinflammatory disorders; however, the mechanisms of regulation of effector and regulatory CD4(+) T cell functions by endogenously activated PPAR-gamma remain unclear. We have used PPAR-gamma-deficient CD4(+) T cells obtained from tissue-specific PPAR-gamma null mice (i.e., PPAR-gamma fl/fl; MMTV-Cre(+)) to investigate the role of endogenous PPAR-gamma on regulatory T cell (Treg) and effector CD4(+) T cell function. Overall, we show that the loss of PPAR-gamma, results in enhanced Ag-specific proliferation and overproduction of IFN-gamma in response to IL-12. These findings correlate in vivo with enhanced susceptibility of tissue-specific PPAR-gamma null mice to trinitrobenzene sulfonic acid-induced colitis. Furthermore, the transfer of purified PPAR-gamma null CD4+ T cells into SCID recipients results in enteric disease. To test the assertion that the deficiency of PPAR-gamma in Treg impairs their ability to prevent effector T cell-induced colitis, we performed cotransfer studies. These studies demonstrate that PPAR-gamma-expressing, but not PPAR-gamma null Treg, prevent colitis induced by transfer of naive CD4(+) T cells into SCID recipients. In line with these findings, the production of IFN-gamma by spleen and mesenteric lymph node-derived CD4(+) T cells was down-regulated following transfer of PPAR-gamma-expressing, but not PPAR-gamma null, Treg. In conclusion, our data suggest that endogenous PPAR-gamma activation represents a Treg intrinsic mechanism of down-regulation of effector CD4(+) T cell function and prevention of colitis.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据